Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC18A2 | Q05940 | 11/20 | 0.34 |
| ▸ | F2 | P00734 | 4/20 | 0.32 |
| ▸ | APLNR | P35414 | 1/20 | 0.32 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.32 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.32 |
| ▸ | HIF1A | Q16665 | 2/20 | 0.32 |
| ▸ | MEN1 | O00255 | 2/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.32 |
| ▸ | TP53 | P04637 | 1/20 | 0.32 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.32 |
| ▸ | THPO | P40225 | 1/20 | 0.32 |
| ▸ | STAT6 | P42226 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | HTT | P42858 | 1/20 | 0.32 |
| ▸ | NPC1 | O15118 | 1/20 | 0.32 |
| ▸ | RBBP9 | O75884 | 1/20 | 0.32 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.32 |
| ▸ | HTR1A | P08908 | 1/20 | 0.32 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19084238 | 0.93 | SLC18A2 (0.33) | SLC18A2F2APLNR | |
| SCHEMBL15745484 | 0.87 | CRHR1 (0.35) | SLC18A2F2APLNR | |
| SCHEMBL15744730 | 0.87 | APLNR (0.36) | SLC18A2APLNR | |
| SCHEMBL15744674 | 0.85 | CRHR1 (0.34) | SLC18A2F2APLNR | |
| SCHEMBL19084167 | 0.79 | APLNR (0.34) | SLC18A2F2APLNR | |
| SCHEMBL15745527 | 0.77 | APLNR (0.37) | SLC18A2APLNR | |
| SCHEMBL15744685 | 0.76 | APLNR (0.36) | SLC18A2APLNR | |
| SCHEMBL26404165 | 0.76 | SLC18A2 (0.33) | SLC18A2CYP3A4MAPK1HIF1AMEN1 | |
| SCHEMBL26404291 | 0.75 | SLC18A2 (0.34) | SLC18A2APLNRCYP3A4MAPK1HIF1A | |
| SCHEMBL26554013 | 0.71 | HTR1A (0.43) | SLC18A2CYP3A4MAPK1HIF1AMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9492560-B2 | Emetine derivatives, prodrugs containing same, and methods of treating conditions using same | HOWARD UNIVERSITY | 2016-11-15 | — | — | US | disclosed |
| US-20140148377-A1 | Emetine Derivatives, Prodrugs Containing Same, And Methods Of Treating Conditions Using Same | HOWARD UNIVERSITY | 2014-05-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140148377-A1 | Emetine Derivatives, Prodrugs Containing Same, And Methods Of Treating Conditions Using Same | EML4, MCL1, ERAP2 | SLC18A2 1893/4885F2 2994/4885APLNR 1503/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.